Preliminary data from the Phase 3 EVOLVE-MS-1 trial shows that ALKS 8700 — an investigative therapy developed by Alkermes to treat relapsing forms of multiple sclerosis (MS) — has a good safety and tolerability profile.
The results were subject of a poster, “EVOLVE-MS-1: A Phase 3, Open-Label, Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis,” that was presented Oct. 27 at the 7th Joint ECTRIMS-ACTRIMS Meeting in Paris.
ALKS 8700 is an oral compound. Once inside the body, it is rapidly transformed into the therapeutic compound monomethyl fumarate (MMF). Although similar, this drug candidate was designed to offer features different than those achieved with the commercially available Tecfidera (dimethyl fumarate).
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services.
…………………………………………………………………….
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews